查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827372

體外診斷市場按產品類型、測試類型、檢體、應用和最終用戶分類－2025-2032 年全球預測

In-Vitro Diagnostics Market by Product Type, Test Type, Specimen, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年體外診斷市場規模將成長至 1,371.2 億美元，複合年成長率為 6.96%。

主要市場統計數據
基準年2024年 799.9億美元
預計2025年 851.6億美元
預測年份：2032年 1371.2億美元
複合年成長率（%） 6.96%

現代體外診斷領域的策略方向，強調技術融合、臨床要求和業務重點

體外診斷處於臨床需求、技術創新和醫療體系經濟的交匯點，相關人員需要清晰、可操作的資訊來駕馭這個快速發展的領域。本報告首先將診斷置於現代臨床工作流程中，重點介紹儀器、檢測設計和數位分析的進展如何重塑診斷路徑。然後，報告追溯了其對實驗室、醫院和照護現場機構的實際影響，並認知到營運壓力和監管期望如何影響引進週期和投資決策。

引言從背景到結果，概述了變革的核心要素——技術融合、醫療服務模式轉變和供應鏈重組——並解釋了這些要素對經營團隊、臨床領導者和技術供應商的重要性。本書強調，需要製定平衡臨床績效、成本效益和法規遵循的策略，同時保持彈性以適應新的公共衛生需求。本章概述了後續分析的結構，闡明如何將複雜的動態轉化為優先考慮的因素和可操作的建議，以幫助相關人員獲得競爭優勢和臨床優勢。

自動化、數位分析、照護現場擴展和不斷變化的法規如何重塑診斷開發、交付和營運策略

診斷領域正在經歷一系列變革性轉變，這些轉變正在重新定義診斷技術的開發、檢驗和在臨床實踐中的部署方式。自動化和定序技術的進步正在實現更高的通量和更廣泛的檢測選單，而診斷軟體與雲端原生分析技術的整合正在將原始檢測結果轉化為可操作的臨床情報。因此，決策者必須將傳統的資本密集型實驗室投資與強調敏捷性和持續改進的新型軟體優先模式相協調。

同時，即時檢測正從快速抗原模型向更精密的分析儀和緊湊的分子平台發展，使診斷能力更貼近患者，並加快了臨床決策時間。法律規範也在不斷發展，以適應軟體作為醫療設備，並簡化伴隨診斷的流程，這既創造了機遇，也增加了合規的複雜性。此外，供應鏈的彈性和關鍵零件的資源配置現已成為策略重點，這體現在採購標準和夥伴關係策略中。總而言之，這些轉變促使人們重新評估產品藍圖、商業化策略和臨床檢驗方法，並要求採取協調商業、臨床和營運目標的全面應對措施。

不斷變化的關稅趨勢迫使診斷提供者和買家重新設計其採購、物流和商業化策略，以保持供應的連續性和有競爭力的價格。

2025年美國關稅環境為診斷供應鏈、採購定價和籌資策略帶來了巨大壓力，迫使相關人員重新評估供應商關係和零件依賴關係。關稅導致進口試劑、耗材和儀器零件成本上漲，凸顯了供應鏈透明度和多源採購策略的重要性。採購團隊加快了二級供應商的資質審核，供應商也調整了商業模式，透過本地製造、重新談判或重新設計產品來應對不斷上升的到岸成本，從而減少對關稅投入品的依賴。

同時，監管和海關合規負擔加重，文件記錄、分類準確性和跨境物流規劃也更加重要。臨床實驗室和經銷商已採取應對措施，加強庫存管理，並協商簽訂長期契約，以確保價格可預測性和供應的連續性。重要的是，關稅情勢刺激了對區域製造中心和合作聯盟的策略性投資，旨在減少對單一國家採購的依賴。因此，關稅趨勢不再是短期採購的複雜因素，而是成為影響整個診斷價值鏈資本配置、定價策略和夥伴關係模式的持久因素。

綜合細分分析揭示了產品類型、測試方式、檢體考量、臨床應用和最終用戶動態的交集，從而創造了策略機遇

當分析圍繞著關鍵細分框架（產品、測試、檢體、應用程式和最終用戶類別）進行時，對需求促進因素和採用模式的洞察最為清晰。根據產品類型，我們檢視儀器、試劑和試劑套件以及軟體和服務，其中儀器分為分析儀、自動化系統和定序儀器，軟體和服務分為校準服務、諮詢服務、診斷軟體和維護服務。這個視角揭示了資本設備生命週期、耗材依賴關係和業務收益如何相互作用，從而塑造供應商策略和客戶採購偏好。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 就地檢驗的日益普及正在顯著改變體外診斷領域
  • 增加家用 IVD套件的可用性，以改善患者的便利性和監測
  • 自動化技術的進步加速了體外診斷實驗室的工作流程
  • 整合人工智慧，提高體外檢測的診斷準確性和效率
  • 個人化醫療的不斷擴展推動了對先進體外診斷工具的需求
  • 分子診斷作為疾病檢測和管理的關鍵組成部分的出現
  • 政府資金增加將促進體外診斷領域的研發
  • 開發能夠同時檢測多種生物標記的多重檢測方法
  • 促進新型體外診斷方法的創新和投資，並專注於早期疾病檢測
  • 監管改革塑造市場動態並確保體外診斷的更高品質標準

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章體外診斷市場（依產品類型）

  • 裝置
    • 分析器
    • 自動化系統
    • 定序設備
  • 試劑和套件
  • 軟體和服務
    • 校對服務
    • 諮詢服務
    • 診斷軟體
    • 維護服務

第9章體外診斷市場（依測試類型）

  • 臨床化學
    • 血液檢查
    • 電解質面板
    • 肝臟檢查
    • 甲狀腺功能檢查
    • 尿液檢查
  • 血液學
  • 免疫檢測
  • 微生物學
  • 分子診斷

第 10 章體外診斷市場（依檢體）

  • 血液、血清、血漿
  • 唾液
  • 組織樣本
  • 尿

第11章體外診斷市場（依應用）

  • 自體免疫疾病
  • 癌症檢測
  • 心臟監測
  • 糖尿病管理
  • 基因檢測
  • 傳染病檢查

第 12 章體外診斷市場（依最終用戶）

  • 學術研究中心
  • 診斷實驗室
  • 醫院
  • 就地檢驗中心

第13章體外診斷市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章體外診斷市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章體外診斷市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Agappe Diagnostics Ltd.
    • ARKRAY Inc.
    • Asahi Kasei Pharma Corporation
    • Becton, Dickinson and Company
    • Edan Instruments, Inc.
    • Grifols SA
    • HiMedia Laboratories Pvt. Ltd.
    • Hitachi Ltd.
    • Hologic, Inc.
    • J Mitra & Co. Pvt. Ltd.
    • KAINOS Laboratories, Inc.
    • Kyowa Medex Co., Ltd.
    • Meril Diagnostics Pvt. Ltd.
    • Mindray Bio-Medical Electronics Co., Ltd.
    • Nihon Kohden Corporation
    • PerkinElmer, Inc.
    • Sekisui Medical Co., Ltd.
    • Shanghai Kehua Bio-engineering Co., Ltd.
    • Siemens AG
    • Sino Biopharmaceutical Limited
    • Sysmex Corporation
    • Thermo Fisher Scientific, Inc.
    • Tosoh Corporation
    • Transasia Bio-Medicals Ltd.
    • Zhejiang Orient Gene Biotech Co
Product Code: MRR-434CCDA04D33

The In-Vitro Diagnostics Market is projected to grow by USD 137.12 billion at a CAGR of 6.96% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 79.99 billion
Estimated Year [2025] USD 85.16 billion
Forecast Year [2032] USD 137.12 billion
CAGR (%) 6.96%

A strategic orientation to the contemporary in-vitro diagnostics environment that frames technological convergence, clinical imperatives, and operational priorities for leaders

In-vitro diagnostics sit at the intersection of clinical need, technological innovation, and health-system economics, and stakeholders require clear, actionable intelligence to navigate this rapidly evolving field. The report opens by situating diagnostics within contemporary clinical workflows, highlighting how advances in instrumentation, assay design, and digital analytics are reshaping diagnostic pathways. It then traces the practical implications for laboratories, hospitals, and point-of-care settings, acknowledging how operational pressures and regulatory expectations influence adoption cycles and investment decisions.

Moving from context to consequence, the introduction frames the core vectors of change-technology convergence, shifting care delivery models, and supply chain recalibration-and explains why these vectors matter to executive teams, clinical leaders, and technology vendors. It emphasizes the need for strategies that balance clinical performance with cost-efficiency and regulatory compliance, while also preserving the agility to adapt to emergent public health demands. The narrative closes by outlining the structure of the analysis that follows, clarifying how subsequent sections translate complex dynamics into prioritized insights and practical recommendations for stakeholders seeking competitive and clinical advantage.

How automation, digital analytics, point-of-care expansion, and regulatory evolution are collectively reshaping diagnostic development, delivery, and operational strategy

The diagnostics landscape is experiencing a series of transformative shifts that are redefining how diagnostics are developed, validated, and deployed across care settings. Advances in automation and sequencing technologies are enabling higher throughput and broader test menus, while the integration of diagnostic software and cloud-native analytics is turning raw assay outputs into actionable clinical intelligence. As a result, decision-makers must reconcile traditional capital-intensive laboratory investments with emerging software-first models that emphasize agility and continuous improvement.

Concurrently, point-of-care testing is moving beyond rapid antigen models to embrace more sophisticated analyzers and compact molecular platforms, shifting diagnostic capacity closer to patients and accelerating clinical decision timelines. Regulatory frameworks are also evolving to address software as a medical device and to streamline pathways for companion diagnostics, creating both opportunities and compliance complexities. Moreover, supply chain resilience and the reshoring of critical components are now strategic priorities, informing procurement criteria and partnership strategies. Taken together, these shifts are prompting a re-evaluation of product road maps, commercialization strategies, and clinical validation approaches, and they demand integrated responses that align commercial, clinical, and operational objectives.

Evolving tariff dynamics have forced diagnostic providers and buyers to redesign sourcing, logistics, and commercialization strategies to preserve supply continuity and competitive pricing

The U.S. tariff environment in 2025 introduced substantive pressures across diagnostic supply chains, procurement pricing, and sourcing strategies, compelling stakeholders to reassess vendor relationships and component dependencies. Tariff-driven cost increases for imported reagents, consumables, and select instrumentation components have translated into sharper prioritization of supply chain transparency and multi-sourcing strategies. Procurement teams have accelerated qualification of secondary suppliers, and vendors have adjusted commercial models to accommodate increased landed costs through localized manufacturing, renegotiated terms, or product redesign that lowers exposure to tariffed inputs.

In parallel, regulatory and customs compliance burdens have grown, prompting greater emphasis on documentation, classification accuracy, and cross-border logistics planning. Clinical laboratories and distributors have responded by enhancing inventory management and by negotiating longer-term contracts that provide price predictability and supply continuity. Importantly, the tariff landscape has stimulated strategic investment in regional manufacturing hubs and collaborative alliances aimed at reducing reliance on single-country sourcing. Consequently, tariff dynamics are no longer a short-term procurement complication but an enduring factor shaping capital allocation, pricing strategies, and partnership models across the diagnostics value chain.

Integrated segmentation analysis revealing where product types, test modalities, specimen considerations, clinical applications, and end-user dynamics intersect to create strategic opportunities

Insight into demand drivers and adoption patterns emerges most clearly when analysis is structured around the primary segmentation frameworks used by product, test, specimen, application, and end-user categories. Based on product type, the landscape is studied across Instruments, Reagents & Kits, and Software & Services, with Instruments further analyzed through Analyzers, Automation Systems, and Sequencing Instruments, and Software & Services further divided into Calibration Services, Consultancy Services, Diagnostic Software, and Maintenance Services. This lens reveals how capital equipment lifecycles, consumable dependencies, and service revenues interact to shape vendor strategies and client procurement preferences.

Based on test type, the study examines Clinical Chemistry, Hematology, Immunoassays, Microbiology, and Molecular Diagnostics, with Clinical Chemistry further detailed across Blood Analysis, Electrolyte Panel, Liver Panel, Thyroid Function Panel, and Urine Analysis. This taxonomy highlights where clinical demand is concentrated and where innovation-such as multiplex assays or digital interpretation-creates differentiation. Based on specimen, the analysis covers Blood, Serum & Plasma, Saliva, Tissue Samples, and Urine, indicating how specimen type influences sample handling workflows and pre-analytical requirements. Based on application, the study considers Autoimmune Diseases, Cancer Detection, Cardiac Monitoring, Diabetes Management, Genetic Testing, and Infectious Disease Testing to clarify clinical use cases that drive adoption. Finally, based on end user, the work assesses Academic & Research Centers, Diagnostic Laboratories, Hospitals, and Point-Of-Care Testing Centers to illuminate procurement cycles, reimbursement sensitivities, and operational readiness. By integrating these segmentation dimensions, the analysis surfaces which product-test-specimen-application-end user combinations present the clearest pathways for product differentiation, clinical validation prioritization, and tailored go-to-market execution.

How differing regulatory regimes, healthcare infrastructures, and procurement behaviors across global regions are influencing diagnostic adoption patterns and commercial strategies

Regional dynamics are shaping competitive strategies and deployment priorities in distinctly different ways across the world's major geographies. In the Americas, demand is driven by a combination of mature laboratory networks, large private payers, and a strong emphasis on value-based care models that reward diagnostic accuracy and time-to-result improvements. Consequently, suppliers operating in this region often emphasize high-throughput instruments, comprehensive reagent portfolios, and compatibility with centralized laboratory information systems to meet the needs of large hospital networks and reference laboratories.

In Europe, Middle East & Africa, regulatory harmonization initiatives and heterogeneous reimbursement environments produce a fragmented adoption landscape. Manufacturers and distributors must navigate diverse national regulatory requirements while adapting pricing and service models to varied procurement practices. Strategic partnerships and localized service capabilities are therefore critical to achieving traction. In Asia-Pacific, rapid expansion of diagnostic capacity, significant public health investment, and the proliferation of private healthcare providers are driving demand for scalable automation, molecular testing platforms, and decentralized testing solutions. Across these regions, differences in supply chain maturity, regulatory timelines, and clinical priorities inform how vendors sequence market entry, allocate resources for clinical validation, and structure commercial partnerships.

Competitive differentiation increasingly depends on integrated product ecosystems, strategic partnerships, and service-led business models that secure clinical trust and recurring revenue

Competitive positioning in this sector is increasingly determined by a company's ability to combine technical excellence with service capabilities and strategic partnerships. Leading firms differentiate through integrated solutions that couple high-performance instruments with proprietary reagents and robust software ecosystems that enable data-driven insights. Other players focus on niche specialization, providing best-in-class assays or compact platforms tailored for point-of-care environments, and they leverage clinical partnerships to validate performance and accelerate clinical adoption.

Partnership strategies are also central to growth, with collaborations spanning co-development, distribution alliances, and service networks that expand geographic reach. Meanwhile, aftermarket services such as calibration, maintenance, and consultancy not only create recurring revenue streams but also deepen customer relationships and reduce churn. New entrants tend to compete on speed of innovation and focused clinical use cases, while incumbent vendors emphasize scale, regulatory experience, and established relationships with health systems. Taken together, these dynamics underscore the importance of aligning product road maps, commercial models, and service delivery to capture clinical trust and long-term contracts.

Practical strategic actions to align platform design, regulatory preparedness, supply resilience, and service expansion to convert technical innovation into enduring commercial advantage

Industry leaders should adopt a coordinated set of actions that align R&D, regulatory strategy, and commercial execution to capture near-term clinical needs while building long-term resilience. First, prioritize modular platform architectures that support both centralized high-throughput analytics and decentralized point-of-care deployments, enabling flexible responses to diverse customer segments. Second, invest in regulatory-readiness early in product development, particularly for software-driven diagnostics, to reduce time-to-qualification and to minimize adaptation costs across jurisdictions. Third, strengthen supply chain resilience through supplier diversification, regional manufacturing partnerships, and strategic inventory management to buffer against tariff and logistics volatility.

Furthermore, expand service portfolios to include calibration, maintenance, and consultancy offerings that embed products within customer workflows and create recurring revenue. Leverage real-world performance data to build clinical and economic evidence packages that support reimbursement discussions and drive clinician confidence. Finally, pursue selective partnerships with clinical networks and academic centers to accelerate validation and to demonstrate clinical utility in high-impact applications. These combined actions will help organizations convert technical capability into enduring commercial advantage while mitigating regulatory and supply-side risks.

A rigorous mixed-methods research approach combining primary stakeholder interviews, technical validation, and scenario stress-testing to ensure credible and actionable insights

The research underpinning this analysis employed a layered methodology that integrates primary interviews, technical document review, and structured triangulation to ensure robustness and relevance. Primary research included in-depth interviews with laboratory directors, procurement leads, clinical specialists, and senior executives from equipment and reagent suppliers to capture current decision criteria, operational constraints, and strategic priorities. These qualitative inputs were complemented by systematic review of regulatory guidance, clinical literature, and product technical specifications to validate performance claims and to map regulatory pathways.

Quantitative validation was achieved through cross-referencing procurement patterns, device filings, and published clinical evaluation studies, enabling a consolidated view of adoption drivers and technical trade-offs. Throughout the process, findings were stress-tested through advisor reviews and scenario analysis to identify sensitivities and to surface practical mitigation approaches. Data governance practices ensured traceability and confidentiality of primary inputs, and methodological limitations were identified explicitly to contextualize interpretation. This rigorous, mixed-methods approach supports credible, actionable insights that are directly relevant to commercial planning and clinical strategy.

Consolidated strategic conclusions emphasizing the imperative to align technological innovation, clinical evidence, and operational resilience to secure long-term adoption and commercial success

In-vitro diagnostics are poised to remain a strategic lever for improving patient outcomes and for optimizing care pathways, provided that industry actors align technological innovation with pragmatic commercial and operational strategies. The synthesis presented here emphasizes that success will come to those organizations that integrate platform flexibility, robust validation evidence, and resilient supply chain models into their value propositions. Equally important is the ability to translate technical differentiation into service models that deepen customer relationships and provide predictable revenue streams.

Looking ahead, leaders must remain vigilant to regulatory evolution, to shifting care delivery patterns that favor decentralization, and to macroeconomic forces that affect sourcing and pricing. By prioritizing interoperability, evidence generation, and regional adaptability, stakeholders can convert complexity into competitive advantage. Ultimately, the capacity to synthesize clinical relevance with operational feasibility will determine which technologies achieve lasting clinical adoption and commercial traction.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of point-of-care testing significantly transforming in-vitro diagnostics landscape
  • 5.2. Growth in home-based in-vitro diagnostic kits improving patient convenience and monitoring
  • 5.3. Advancements in automation technology accelerating in-vitro diagnostic laboratory workflows
  • 5.4. Integration of artificial intelligence enhancing diagnostic accuracy and efficiency in in-vitro testing
  • 5.5. Expansion of personalized medicine driving demand for advanced in-vitro diagnostic tools
  • 5.6. Emergence of molecular diagnostics as a critical component in disease detection and management
  • 5.7. Increasing government funding boosting research and development in in-vitro diagnostics sector
  • 5.8. Development of multiplex assays enabling simultaneous detection of multiple biomarkers
  • 5.9. Focus on early disease detection fueling innovation and investment in novel in-vitro diagnostic methods
  • 5.10. Regulatory reforms shaping market dynamics and ensuring higher quality standards in in-vitro diagnostics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In-Vitro Diagnostics Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Analyzers
    • 8.1.2. Automation Systems
    • 8.1.3. Sequencing Instrument
  • 8.2. Reagents & Kits
  • 8.3. Software & Services
    • 8.3.1. Calibration Services
    • 8.3.2. Consultancy Services
    • 8.3.3. Diagnostic Software
    • 8.3.4. Maintenance Services

9. In-Vitro Diagnostics Market, by Test Type

  • 9.1. Clinical Chemistry
    • 9.1.1. Blood Analysis
    • 9.1.2. Electrolyte Panel
    • 9.1.3. Liver Panel
    • 9.1.4. Thyroid Function Panel
    • 9.1.5. Urine Analysis
  • 9.2. Hematology
  • 9.3. Immunoassays
  • 9.4. Microbiology
  • 9.5. Molecular Diagnostics

10. In-Vitro Diagnostics Market, by Specimen

  • 10.1. Blood, Serum & Plasma
  • 10.2. Saliva
  • 10.3. Tissue Samples
  • 10.4. Urine

11. In-Vitro Diagnostics Market, by Application

  • 11.1. Autoimmune Diseases
  • 11.2. Cancer Detection
  • 11.3. Cardiac Monitoring
  • 11.4. Diabetes Management
  • 11.5. Genetic Testing
  • 11.6. Infectious Disease Testing

12. In-Vitro Diagnostics Market, by End User

  • 12.1. Academic & Research Centers
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Point-Of-Care Testing Centers

13. In-Vitro Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. In-Vitro Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. In-Vitro Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Agappe Diagnostics Ltd.
    • 16.3.2. ARKRAY Inc.
    • 16.3.3. Asahi Kasei Pharma Corporation
    • 16.3.4. Becton, Dickinson and Company
    • 16.3.5. Edan Instruments, Inc.
    • 16.3.6. Grifols S.A.
    • 16.3.7. HiMedia Laboratories Pvt. Ltd.
    • 16.3.8. Hitachi Ltd.
    • 16.3.9. Hologic, Inc.
    • 16.3.10. J Mitra & Co. Pvt. Ltd.
    • 16.3.11. KAINOS Laboratories, Inc.
    • 16.3.12. Kyowa Medex Co., Ltd.
    • 16.3.13. Meril Diagnostics Pvt. Ltd.
    • 16.3.14. Mindray Bio-Medical Electronics Co., Ltd.
    • 16.3.15. Nihon Kohden Corporation
    • 16.3.16. PerkinElmer, Inc.
    • 16.3.17. Sekisui Medical Co., Ltd.
    • 16.3.18. Shanghai Kehua Bio-engineering Co., Ltd.
    • 16.3.19. Siemens AG
    • 16.3.20. Sino Biopharmaceutical Limited
    • 16.3.21. Sysmex Corporation
    • 16.3.22. Thermo Fisher Scientific, Inc.
    • 16.3.23. Tosoh Corporation
    • 16.3.24. Transasia Bio-Medicals Ltd.
    • 16.3.25. Zhejiang Orient Gene Biotech Co

LIST OF FIGURES

  • FIGURE 1. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEQUENCING INSTRUMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEQUENCING INSTRUMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEQUENCING INSTRUMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEQUENCING INSTRUMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEQUENCING INSTRUMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEQUENCING INSTRUMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CALIBRATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CALIBRATION SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CALIBRATION SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CALIBRATION SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CALIBRATION SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CALIBRATION SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CONSULTANCY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CONSULTANCY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CONSULTANCY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CONSULTANCY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CONSULTANCY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CONSULTANCY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TISSUE SAMPLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TISSUE SAMPLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TISSUE SAMPLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TISSUE SAMPLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANCER DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANCER DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANCER DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANCER DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANCER DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANCER DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIAC MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIAC MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIAC MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIAC MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIAC MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIAC MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)

TABLE 314